Drug Profile
Research programme: BLI 1004 - Biolite
Alternative Names: BLI-1004Latest Information Update: 07 Sep 2020
Price :
$50
*
At a glance
- Originator BioLite Inc
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cervical cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cervical-cancer in Taiwan
- 30 Jan 2013 Preclinical trials in Cervical cancer in Taiwan (unspecified route)